Search Bar & Filters
Found 137 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying obstructive sleep apnea syndrome OSAS, a sleep disorder marked by loud snoring and repeated airway blockages during sleep that cause daytime tiredness. This observational study aims to create a prospective database to track changes in the upper airway volume and anatomy after maxillomandibular advancement MMA surgery, along with measuring the apnea-hypopnea index AHI and patients quality of life. The study collects detailed data on patient demographics, virtual 3D cone-beam CT CBCT surgical planning, orthognathic surgery details, sleep study results, and quality of life assessments as part of routine care.
Actively Recruiting
Researchers are evaluating treatments for germinal center B-cell-like diffuse large B-cell lymphoma GCB DLBCL, a fast-growing blood cancer affecting immature B-cells. The study aims to determine if more people respond to zilovertamab vedotin MK-2140 combined with R-CHP compared to polatuzumab vedotin combined with R-CHP. This is a phase 2 randomized study focused on participants who have not been treated before and have the GCB subtype of DLBCL. Participants will be randomly assigned to receive either zilovertamab vedotin plus cyclophosphamide, doxorubicin, rituximab or its biosimilar R-CHP, or polatuzumab vedotin plus R-CHP. These drugs are given by intravenous infusion on Day 1 of each 3-week cycle for up to 6 cycles, about 4 months. Additionally, participants take prednisone or prednisolone tablets daily on Days 1 to 5 of each cycle. Those with high-risk DLBCL may receive 2 extra cycles of rituximab or its biosimilar. Throughout the study, participants undergo assessments including PET scans to monitor cancer response, and various health evaluations. Researchers measure complete response rate at the end of treatment, progression-free survival, overall survival, event-free survival, and quality of life using standardized tools. Safety is monitored by tracking adverse events and treatment tolerability. The study lasts up to several years with follow-up for long-term outcomes.
Actively Recruiting
Researchers are evaluating the long-term safety, tolerability, and lasting effects of ALKS 2680 tablets in adults with Narcolepsy Type 1, Narcolepsy Type 2, or Idiopathic Hypersomnia. This study involves participants who have completed earlier ALKS 2680 parent studies and aims to continue monitoring treatment impact over an extended period. Participants receive oral ALKS 2680 tablets once daily at doses ranging from 4 mg to 18 mg. The study follows a non-randomized, open-label design, and includes three groups based on the specific condition Narcolepsy Type 1, Narcolepsy Type 2, and Idiopathic Hypersomnia. The treatment duration extends up to 248 weeks, allowing long-term observation of the medications effects. During the study, participants undergo regular assessments including monitoring for adverse events, changes in sleep latency using the Maintenance of Wakefulness Test, sleepiness severity via the Epworth Sleepiness Scale, weekly cataplexy rate, and idiopathic hypersomnia severity. Safety and treatment effects are tracked throughout the study period, which may last up to nearly five years, ensuring ongoing evaluation of participant health and treatment durability.
Actively Recruiting
Researchers are evaluating the safety and effects of a medicine called Fosmanogepix for treating candidemia and invasive candidiasis, serious fungal infections caused by Candida species. This Phase 3 study compares Fosmanogepix with standard treatments to see if it works at least as well as current therapies. The trial involves adult patients diagnosed with these infections, aiming to assess treatment success and patient survival. Participants receive one of two treatments two-thirds get Fosmanogepix through an intravenous IV infusion daily at the clinic, with an option to switch to oral tablets if well enough to continue treatment at home. One-third receive the standard care of Caspofungin IV infusion followed by oral Fluconazole capsules. Matching placebos are used for blinding. Treatment can last up to 6 weeks depending on infection clearance and symptom improvement. During the study, participants undergo regular assessments including blood tests and monitoring for treatment success and safety. Researchers measure survival at 30 days and response rates at multiple time points, including after treatment ends and at a 6-week follow-up. The study tracks adverse events, lab abnormalities, and drug levels to evaluate safety and treatment effects. Total participation can last up to about 12.5 weeks with follow-up visits to monitor long-term outcomes.
Actively Recruiting
Researchers are evaluating the efficacy and safety of fosmanogepix, given either intravenously or orally, for treating adults diagnosed with invasive mold infections. This Phase 3 study focuses on patients infected with molds such as Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug-resistant molds. The goal is to compare the all-cause mortality rate by Day 42 after treatment begins. Participants will be assigned to one of two groups Cohort A includes patients receiving either fosmanogepix or the best available standard antifungal therapy, while Cohort B includes patients who did not respond to previous treatments and will receive fosmanogepix only. Fosmanogepix is administered as an intravenous infusion or oral tablet. The study treatment duration is targeted at 84 days but may be extended up to 180 days, followed by a follow-up period. During the study, participants will undergo various assessments including monitoring of mortality rates, treatment responses clinical, mycological, and radiological, and safety evaluations for adverse events and laboratory abnormalities up to approximately 8 months. Blood samples will be collected at specified timepoints to measure drug concentrations. Electrocardiograms and neurological exams will also be conducted during follow-up to monitor safety and treatment effects.
Actively Recruiting
Researchers are studying an investigational drug called linvoseltamab in adults who have a moderate risk of developing multiple myeloma. This group includes patients with precancerous conditions known as High-Risk Monoclonal Gammopathy of Undetermined Significance HR-MGUS and Non-High-Risk Smoldering Multiple Myeloma NHR-SMM. The main goal is to understand how well linvoseltamab can eliminate abnormal plasma cells and laboratory signs associated with these conditions. Participants will receive linvoseltamab following a step-up dosing regimen to assess safety and tolerability before moving to one of four full dosing regimens. The study is divided into a safety run-in phase and an expansion phase where participants are assigned to different dose groups without randomization. Linvoseltamab is given according to the study protocol, with dosing schedules designed to monitor effects and side effects. During the study, participants will be closely monitored through regular safety observations over 35 days and longer-term assessments up to 5.5 years. Researchers will track adverse events, treatment responses including complete response rates, laboratory results, and the presence of antibodies against the drug. Blood levels of linvoseltamab are measured up to 9 months. This comprehensive monitoring will help understand the drugs impact and safety over time.
Actively Recruiting
Researchers are evaluating a new approach to selecting biologic treatments for adults with active Crohns Disease CD. This prospective, randomized study compares standard treatment selection to a method guided by epigenetic markers, aiming to assess which method better induces clinical remission and improves endoscopic response. The trial includes patients who are either new to biologic therapy or have used no more than one prior biologic treatment. The study is designed to measure efficacy, safety, and cost-effectiveness of this epigenome-guided approach. Participants are randomly assigned to one of two groups one receives biologic therapy based on epigenetic testing results using a specialized software called EpiPredict, which predicts response to two biologics, Vedolizumab VDZ or Ustekinumab UST. The other group receives biologic treatment chosen by their doctor following usual care guidelines without epigenetic information. Both groups receive their biologic treatments as labeled, with dosing adjustments allowed as needed by the treating physician. Throughout the 26-week treatment phase, participants undergo clinical assessments aligned with their biologic treatment schedules. Follow-up visits continue every six months up to two years, collecting data from medical records and online questionnaires. Researchers will measure clinical remission, endoscopic response, and cost-effectiveness among other outcomes to determine the value of using epigenetic markers in treatment selection for Crohns Disease.
Actively Recruiting
This research aims to evaluate the safety and feasibility of a new paddle-shaped, high-density, multi-electrode catheter designed for mapping the atrial and ventricular regions of the heart in patients with various types of cardiac arrhythmias. The study includes adults diagnosed with arrhythmias such as ventricular tachycardia, atrial fibrillation, atrial tachycardia, and premature ventricular contraction who are scheduled for clinically indicated mapping and ablation procedures. Participants will undergo mapping using the investigational catheter during their planned ablation procedure. The catheter is used solely for mapping and not for treatment. The study observes the completion of all required mapping steps before ablation and any additional clinically necessary mapping. The investigational catheter is evaluated for deployment, visualization, maneuverability, and signal quality during the procedure. During the study, participants will be monitored for serious and non-serious adverse events related to the catheter for up to seven days after the procedure. Researchers will assess the safety of the device and whether pre-ablation mapping requirements are met. Participants will undergo standard clinical care alongside study assessments, with follow-up evaluations focusing on safety and device performance shortly after the mapping procedure.
Actively Recruiting
Researchers are evaluating the effectiveness of VES-0-D, an investigational wound gel, in treating mild to moderate Diabetic Foot Ulcers DFU. The study aims to compare how well VES-0-D supports wound healing compared to standard wound treatment over an 8-week period. It also investigates wound characteristics relevant to healing and monitors any side effects at the application site. Participants will receive either VES-0-D gel or standard care wound dressings applied every 3 to 4 days for up to 8 weeks or until the wound closes. Applications may be done at home or in the clinic. Weekly clinic visits will be scheduled for assessments and checkups during treatment. Throughout the study, participants will keep a diary of their wound care and any symptoms. Researchers will monitor wound area reduction and use the Bates-Jensen Wound Assessment Tool to evaluate healing progress. Safety data, including any treatment-related adverse events, will also be collected from enrollment through the end of treatment.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of different doses of Pirtobrutinib in adults with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. Part 1 of the study focuses on participants who have received one to three prior treatments, including a covalent Bruton tyrosine kinase BTK inhibitor, while Part 2 studies treatment-nave participants with a specific genetic deletion 17p deletion. This trial is a Phase 2, open-label, randomized study sponsored by Loxo Oncology, Inc. Participants receive Pirtobrutinib orally in varying doses. In Part 1, three different doses are tested in participants with relapsed or refractory CLLSLL who have prior BTK inhibitor treatment. Part 2 evaluates Pirtobrutinib monotherapy at a standard dose in treatment-nave participants with 17p deletions. The study uses a parallel design with random assignment to treatment groups. Participants are involved for approximately three years in Part 1 and up to two years in Part 2. Researchers monitor overall response rate as the primary outcome, along with duration of response over this time. Participants must be able to swallow oral medication and have their health status regularly assessed, including physical performance scores. Safety and treatment effects are followed throughout the study period.
1-10 of 137
1